Escientia Biopharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 12-12-2024
- Paid Up Capital ₹ 1.12 Cr
as on 12-12-2024
- Company Age 16 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -13.83%
(FY 2020)
- Profit -238.98%
(FY 2020)
- Ebitda 69.58%
(FY 2020)
- Net Worth -21.46%
(FY 2020)
- Total Assets 41.61%
(FY 2020)
About Escientia Biopharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.12 Cr, as per Ministry of Corporate Affairs (MCA) records.
Yadagiri Pendri, Pendri Reddy, Vivek Save, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24100TG2008PTC057277
- Company No.
057277
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jan 2008
- Date of AGM
12 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Escientia Biopharma?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vivek Save  | Director | 19-Aug-2020 | Current |
Pendri Reddy  | Director | 10-Nov-2008 | Current |
| Yadagiri Pendri | Director | 22-Jan-2008 | Current |
| Dandu Chakradhar | Director | 19-Aug-2020 | Current |
| Ajit George | Director | 24-Jun-2023 | Current |
| Suresh Partani | Director | 22-Jan-2008 | Current |
Financial Performance and Corporate Structure Insights of Escientia Biopharma.
Escientia Biopharma Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 13.83% decrease. The company also saw a substantial fall in profitability, with a 238.98% decrease in profit. The company's net worth observed a substantial decline by a decrease of 21.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Escientia Biopharma?
In 2021, Escientia Biopharma had a promoter holding of 24.81% and a public holding of 75.19%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Escientia Advanced Sciences Private LimitedActive 11 years 9 monthsYadagiri Pendri, Pendri Reddy and 3 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Escientia Biopharma?
Escientia Biopharma has a workforce of 163 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Escientia Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Escientia Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
